Skip to main content
Top
Published in: Clinical Rheumatology 8/2011

Open Access 01-08-2011 | Brief Report

Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity

Authors: Izhar C. van Eijk, Erik H. Serné, Ben A. C. Dijkmans, Yvo Smulders, Michael Nurmohamed

Published in: Clinical Rheumatology | Issue 8/2011

Login to get access

Abstract

Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. Microvascular function has been linked to several risk factors for cardiovascular disease and may be affected in RA. It is, however, presently unknown at what point in the disease course the abnormalities in microvascular function occur. We determined whether microvascular function is already disturbed in early disease-modifying antirheumatic drugs (DMARD)-naive RA patients with low systemic inflammation. Fifteen consecutive RA patients with a median symptom duration of 5 months, a C-reactive protein level of ≤20 mg/l and without a history of cardiovascular disease, and age 15 and sex-matched healthy controls were recruited. Endothelium-dependent and endothelium-independent vasodilatation in skin was evaluated with laser Doppler fluxmetry after iontophoresis of acetylcholine and sodium nitroprusside, respectively. Videomicroscopy was used to measure recruitment of skin capillaries after arterial occlusion. CRP and ESR levels were mildly, but significantly elevated in patients compared to controls. No differences in both endothelium-dependent vasodilatation and capillary recruitment were observed between groups [709% (95% CI, 457–961%) vs 797% (95% CI, 556–1,037%), P = 0.59 and 37% (95% CI, 26–47%) vs 41% (95% CI, 31–50%), P = 0.59, respectively]. Skin microvascular function is preserved in early, DMARD-naive RA patients with moderately active RA but low systemic inflammatory activity. Both the extent of the systemic inflammation and disease duration, therefore, may be important determinants of microvascular dysfunction and subsequent increased risk for cardiovascular disease.
Literature
1.
go back to reference del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMedCrossRef del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMedCrossRef
2.
go back to reference Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP (2002) Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46:2010–2019PubMedCrossRef Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP (2002) Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46:2010–2019PubMedCrossRef
3.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307PubMedCrossRef
4.
go back to reference Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963PubMedCrossRef Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963PubMedCrossRef
5.
go back to reference Del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840PubMedCrossRef Del Rincon I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833–1840PubMedCrossRef
6.
go back to reference Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17PubMedCrossRef Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17PubMedCrossRef
7.
go back to reference Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873PubMedCrossRef Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873PubMedCrossRef
8.
go back to reference Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26:2562–2571PubMed Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26:2562–2571PubMed
9.
go back to reference Del Rincon ID, O’Leary DH, Freeman GL, Escalante A (2007) Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 195:354–360PubMedCrossRef Del Rincon ID, O’Leary DH, Freeman GL, Escalante A (2007) Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 195:354–360PubMedCrossRef
10.
go back to reference Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H (2002) Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 22:1637–1641PubMedCrossRef Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H (2002) Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 22:1637–1641PubMedCrossRef
11.
go back to reference Hansel S, Lassig G, Pistrosch F, Passauer J (2003) Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170:177–180PubMedCrossRef Hansel S, Lassig G, Pistrosch F, Passauer J (2003) Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170:177–180PubMedCrossRef
12.
go back to reference Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM (2007) Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115:2390–2397PubMedCrossRef Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM (2007) Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115:2390–2397PubMedCrossRef
13.
go back to reference Cheung N, Bluemke DA, Klein R, Sharrett AR, Islam FM, Cotch MF, Klein BE, Criqui MH, Wong TY (2007) Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 50:48–55PubMedCrossRef Cheung N, Bluemke DA, Klein R, Sharrett AR, Islam FM, Cotch MF, Klein BE, Criqui MH, Wong TY (2007) Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 50:48–55PubMedCrossRef
14.
go back to reference Serne EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD (2007) Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 50:204–211PubMedCrossRef Serne EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD (2007) Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 50:204–211PubMedCrossRef
15.
go back to reference Struijker-Boudier HA, Rosei AE, Bruneval P, Camici PG, Christ F, Henrion D, Lévy BI, Pries A, Vanoverschelde JL (2007) Evaluation of the microcirculation in hypertension and cardiovascular disease. Eur Heart J 28:2834–2840PubMedCrossRef Struijker-Boudier HA, Rosei AE, Bruneval P, Camici PG, Christ F, Henrion D, Lévy BI, Pries A, Vanoverschelde JL (2007) Evaluation of the microcirculation in hypertension and cardiovascular disease. Eur Heart J 28:2834–2840PubMedCrossRef
16.
go back to reference IJzerman RG, de Jongh RT, Beijk MA, van Weissenbruch MM, Delemarre-van de Waal HA, Serne EH, Stehouwer CD (2003) Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 33:536–542PubMedCrossRef IJzerman RG, de Jongh RT, Beijk MA, van Weissenbruch MM, Delemarre-van de Waal HA, Serne EH, Stehouwer CD (2003) Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 33:536–542PubMedCrossRef
17.
go back to reference Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ (2008) C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 47:1780–1784CrossRef Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ (2008) C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford) 47:1780–1784CrossRef
18.
go back to reference Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N (2007) Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192:391–395PubMedCrossRef Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N (2007) Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 192:391–395PubMedCrossRef
19.
go back to reference Arosio E, De Marchi S, Rigoni A, Prior M, Delva P, Lechi A (2007) Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 25:1273–1278PubMedCrossRef Arosio E, De Marchi S, Rigoni A, Prior M, Delva P, Lechi A (2007) Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 25:1273–1278PubMedCrossRef
20.
go back to reference Ciftci O, Yilmaz S, Topcu S, Caliskan M, Gullu H, Erdogan D, Pamuk BO, Yildirir A, Muderrisoglu H (2007) Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 198:332–337PubMedCrossRef Ciftci O, Yilmaz S, Topcu S, Caliskan M, Gullu H, Erdogan D, Pamuk BO, Yildirir A, Muderrisoglu H (2007) Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 198:332–337PubMedCrossRef
21.
go back to reference Raza K, Banks M, Kitas GD (2005) Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol 32:754–756PubMed Raza K, Banks M, Kitas GD (2005) Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol 32:754–756PubMed
22.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
23.
go back to reference Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, Gans RO (1999) Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 99:896–902PubMed Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, Gans RO (1999) Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 99:896–902PubMed
24.
go back to reference van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, Nurmohamed MT (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis alpha blockade. Ann Rheum Dis 68:362–366PubMedCrossRef van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, Nurmohamed MT (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis alpha blockade. Ann Rheum Dis 68:362–366PubMedCrossRef
25.
go back to reference Serne EH, Gans RO, ter Maaten JC, ter Wee PM, Donker AJ, Stehouwer CD (2001) Capillary recruitment is impaired in essential hypertension and relates to insulin’s metabolic and vascular actions. Cardiovasc Res 49:161–168PubMedCrossRef Serne EH, Gans RO, ter Maaten JC, ter Wee PM, Donker AJ, Stehouwer CD (2001) Capillary recruitment is impaired in essential hypertension and relates to insulin’s metabolic and vascular actions. Cardiovasc Res 49:161–168PubMedCrossRef
26.
go back to reference Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48PubMedCrossRef Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48PubMedCrossRef
27.
go back to reference Schram MT, Stam F, de Jongh RT, de Vries G, van Dijk RA, Serné EH, Lampe D, Nanayakkara PW, Tushuizen ME, Scheffer PG, Schalkwijk CG, Kamper AM, Stehouwer CD (2003) The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial. Atherosclerosis 170:59–72PubMedCrossRef Schram MT, Stam F, de Jongh RT, de Vries G, van Dijk RA, Serné EH, Lampe D, Nanayakkara PW, Tushuizen ME, Scheffer PG, Schalkwijk CG, Kamper AM, Stehouwer CD (2003) The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial. Atherosclerosis 170:59–72PubMedCrossRef
28.
go back to reference Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, de Gast T, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 50:2423–2427PubMedCrossRef Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, de Gast T, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 50:2423–2427PubMedCrossRef
29.
go back to reference de Jongh RT, Serne EH, IJzerman RG, de Vries G, Stehouwer CD (2004) Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109:2529–2535PubMedCrossRef de Jongh RT, Serne EH, IJzerman RG, de Vries G, Stehouwer CD (2004) Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109:2529–2535PubMedCrossRef
30.
Metadata
Title
Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity
Authors
Izhar C. van Eijk
Erik H. Serné
Ben A. C. Dijkmans
Yvo Smulders
Michael Nurmohamed
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1750-1

Other articles of this Issue 8/2011

Clinical Rheumatology 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine